The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Amyloid-related imaging abnormalities in patients with Alzheimer's disease treated with bapineuzumab: a retrospective analysis
Open accessAbstract
Background Amyloid-related imaging abnormalities (ARIA) have been reported in patients with Alzheimer's disease treated with bapineuzumab, a humanised monoclonal antibody against amyloid β. ARIA include MRI signal abnormalities suggestive of vasogenic oedema and sulcal effusions (ARIA-E) and microhaemorrhages and haemosiderin deposits (ARIA-H). Our aim was to investigate the incidence of ARIA during treatment with bapineuzumab, and evaluate associated risk factors.Methods Two neuroradiologists independently reviewed 2572 fluid-attenuated inversion recovery (FLAIR) MRI scans from 262 participants in two phase 2 studies of bapineuzumab and an open-label extension study. Readers were masked to the patient's treatment, APOE ɛ4 genotype, medical history, and demographics. Patients were included in risk analyses if they had no evidence of ARIA-E in their pre-treatment MRI, had received bapineuzumab, and had at least one MRI scan after treatment. We used Kaplan-Meier survival analysis to examine the distribution of incident ARIA-E from the start of bapineuzumab treatment and proportional hazards regression models to assess risk factors associated with ARIA.Findings 210 patients were included in the risk analyses. 36 patients (17%) developed ARIA-E during treatment with bapineuzumab; 15 of these ARIA-E cases (42%) had not been detected previously. 28 of these patients (78%) did not report associated symptoms. Adverse events, reported in eight symptomatic patients, included headache, confusion, and neuropsychiatric and gastrointestinal symptoms. Incident ARIA-H occurred in 17 of the patients with ARIA-E (47%), compared with seven of 177 (4%) patients without ARIA-E. 13 of the 15 patients in whom ARIA were detected in our study received additional treatment infusions while ARIA-E were present, without any associated symptoms. Occurrence of ARIA-E increased with bapineuzumab dose (hazard ratio [HR] 2·24 per 1 mg/kg increase in dose, 95% CI 1·40-3·62; p=0·0008) and presence of APOE ɛ4 alleles (HR 2·55 per allele, 95% CI 1·57-4·12; p=0·0001).Interpretation ARIA consist of a spectrum of imaging findings with variable clinical correlates, and some patients with ARIA-E remain asymptomatic even if treatment is continued. The increased risk of ARIA among APOE ɛ4 carriers, its association with high bapineuzumab dose, and its timecourse in relation to dosing suggest an association between ARIA and alterations in vascular amyloid burden.Funding Elan Corporation, Janssen Alzheimer Immunotherapy, Wyeth Pharmaceuticals, and Pfizer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The main adverse effects associated with administration of certain anti-Aβ mAbs during clinical trials were amyloid related imaging abnormalities (ARIA) identified on magnetic resonance imaging (MRI) scans.”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However one needs to be mindful that escalation of anti-Aβ mAbs dose in APOE ε4 allele carriers may trigger increased rate of vasculotropic adverse events associated with immunization [5, 8, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Accordingly, ApoE genotyping is now increasingly considered an important component of the pre-treatment work-up for anti-amyloid therapies [5, 8, 11, 12].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“The greater incidence of these abnormalities with increasing bapineuzumab dose and number of APOEε4 alleles is consistent with phase 2 findings.11,13”
From Two Phase 3 Trials of Bapineuzumab in Mild-to-Moderate Alzheimer's Disease (2014) · cites this paper as [11]
The cited source says what the claim attributes to it.
In the citing paper
“Some amyloid β antibodies triggered amyloid-related imaging abnormalities (ARIAs) in clinical trials and ARIAs tend to be more frequent in APOE4 carriers [28].”
From Apolipoprotein E metabolism and functions in brain and its role in Alzheimer's disease (2017) · cites this paper as [28]
The cited source says what the claim attributes to it.
In the citing paper
“These included vasogenic edema (ARIA-E) and cerebral microhemorrhages (ARIA-H) that in about 20% of cases are associated with clinical symptoms and signs [13, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“These included vasogenic edema (ARIA-E) and cerebral microhemorrhages (ARIA-H) that in about 20% of cases are associated with clinical symptoms and signs [13, 14].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Frequency of ARIA events and in particular ARIA-E was significantly higher among APOE ε4 allele carriers compared to non-carriers, making the APOE ε4 allele a risk factor for vascular complications of anti-Aβ immunotherapy [5, 8, 14, 15].”
From APOE Genotype Differentially Modulates Effects of Anti-Aβ, Passive Immunization in APP Transgenic Mice (2017) · cites this paper as [14]
The cited source says what the claim attributes to it.
In the citing paper
“Importantly, ApoE ε4 status has gained direct clinical relevance in the anti-amyloid era”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
The cited source says what the claim attributes to it.
In the citing paper
“ε4 carriers, particularly ε4 homozygotes, exhibit a substantially increased risk of amyloid-related imaging abnormalities (ARIA) during treatment with anti-amyloid monoclonal antibodies [2, 5, 8].”
From Plasma ApoE proteotyping for ApoE ε4 stratification in the anti-amyloid therapies era (2026) · cites this paper as [8]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT
Wahlund, L., Barkhof, F., Fazekas, F., Bronge, L., Augustin, M., Sjögren, M., Wallin, A., Adèr, H., Leys, D., Pantoni, L., et al. (2001) · Stroke · doi:10.1161/01.str.32.6.1318 · Cited by 1,838
Pathologic correlates of incidental MRI white matter signal hyperintensities
Fazekas, F., Kleinert, R., Offenbacher, H., Schmidt, R., Kleinert, G., Payer, F., Radner, H., & Lechner, H. (1993) · Neurology · doi:10.1212/wnl.43.9.1683 · Cited by 1,619
Sperling, R. A., Jack, C. R., Black, S. E., Frosch, M. P., Greenberg, S. M., Hyman, B. T., Scheltens, P., Carrillo, M. C., Thies, W., Bednar, M. M., et al. (2011) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2011.05.2351 · Cited by 857
Self-citationPrevalence and risk factors of cerebral microbleeds: The Rotterdam Scan Study
Vernooij, M. W., van der Lugt, A., Ikram, M. A., Wielopolski, P. A., Niessen, W. J., Hofman, A., Krestin, G. P., & Breteler, M. M. B. (2008) · Neurology · doi:10.1212/01.wnl.0000307750.41970.d9 · Cited by 793
A phase 2 multiple ascending dose trial of bapineuzumab in mild to moderate Alzheimer disease
Salloway, S., Sperling, R., Gilman, S., Fox, N. C., Blennow, K., Raskind, M., Sabbagh, M., Honig, L. S., Doody, R., van Dyck, C. H., et al. (2009) · Neurology · doi:10.1212/wnl.0b013e3181c67808 · Cited by 753
Self-citationRinne, J. O., Brooks, D. J., Rossor, M. N., Fox, N. C., Bullock, R., Klunk, W. E., Mathis, C. A., Blennow, K., Barakos, J., Okello, A. A., et al. (2010) · The Lancet Neurology · doi:10.1016/s1474-4422(10)70043-0 · Cited by 701
Self-citationWeller, R. O., Subash, M., Preston, S., Mazanti, I., & Carare, R. O. (2008) · Brain Pathology · doi:10.1111/j.1750-3639.2008.00133.x · Cited by 697
Apolipoprotein E ϵ4 and cerebral hemorrhage associated with amyloid angiopathy
Greenberg, S. M., Rebeck, G. W., Vonsattel, J. P., Gómez‐Isla, T., & Hyman, B. T. (1995) · Annals of Neurology · doi:10.1002/ana.410380219 · Cited by 547
Mechanism of amyloid removal in patients with Alzheimer disease treated with gantenerumab
Ostrowitzki, S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.1538 · Cited by 431
Clinical manifestations of cerebral amyloid angiopathy–related inflammation
Eng, J. A., Frosch, M. P., Choi, K., Rebeck, G. W., & Greenberg, S. M. (2004) · Annals of Neurology · doi:10.1002/ana.10810 · Cited by 417
Cited by
Sorted by citations
Items 301–400 of 506
Automated algorithm to measure changes in medial temporal lobe volume in Alzheimer disease
Kazemifar, S., Drozd, J. J., Rajakumar, N., BORRIE, M. J., & Bartha, R. (2014) · Journal of Neuroscience Methods · doi:10.1016/j.jneumeth.2014.01.033 · Cited by 15
Rauchmann, B., Ghaseminejad, F., Mekala, S., Perneczky, R., & Initiative, A. D. N. (2020) · Radiology · doi:10.1148/radiol.2020191904 · Cited by 14
Structural Neuroimaging of the Medial Temporal Lobe in Alzheimer’s Disease Clinical Trials
Menéndez‐González, M., Alonso, B. D. C., Salas-Pacheco, J. M., & Arias-Carrión, Ó. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150226 · Cited by 15
Reduction of Amyloid in the Brain and Retina After Treatment With IVIG for Mild Cognitive Impairment
Kile, S. J., Au, W. J., Parise, C. A., Sohi, J., Yarbrough, T. L., Czeszynski, A., Johnson, K., Redline, D., Donnel, T., Hankins, A. I., et al. (2020) · American Journal of Alzheimer s Disease & Other Dementias® · doi:10.1177/1533317519899800 · Cited by 15
Angiotensin-Receptor Blockers, Hypertension and Alzheimer Disease
Katayama, T., & Hasebe, N. (2012) · Circulation Journal · doi:10.1253/circj.cj-12-1550 · Cited by 14
Shang, J., Zhong, S., Shang, L., Zeng, Q., Zhao, S., Luo, X., Li, K., Zhang, X., Huang, P., Yan, Y., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01886-5 · Cited by 13
Dumurgier, J., Laplanche, J., Mouton‐Liger, F., Lapalus, P., Indart, S., Prévot, M., Peoc’h, K., Hugon, J., & Paquet, C. (2014) · Journal of Neurology · doi:10.1007/s00415-014-7335-6 · Cited by 14
Cheng, Y.-J., Wang, M., Wang, J., Cui, Z., & Zhao, M. (2023) · European journal of medical research · doi:10.1186/s40001-023-01096-5 · Cited by 13
Storti, B., Gabriel, M. M., Sennfält, S., Canavero, I., Rifino, N., Gatti, L., & Bersano, A. (2023) · Frontiers in Neuroscience · doi:10.3389/fnins.2023.1219025 · Cited by 13
Translational Research in Neurology
Honig, L. S. (2012) · Archives of Neurology · doi:10.1001/archneurol.2011.2883 · Cited by 13
Self-citationValidation of an MRI Rating Scale for Amyloid‐Related Imaging Abnormalities
Bechten, A., Wattjes, M. P., Purcell, D. D., Aliaga, E. S., Daams, M., Brashear, H. R., Arrighi, H. M., & Barkhof, F. (2017) · Journal of Neuroimaging · doi:10.1111/jon.12422 · Cited by 13
Self-citationCharidimou, A., & Werring, D. J. (2014) · Journal of the Neurological Sciences · doi:10.1016/j.jns.2014.03.004 · Cited by 13
Kimura, A., Takemura, M., Saito, K., Yoshikura, N., Hayashi, Y., Harada, N., Nishida, H., Nakajima, H., & Inuzuka, T. (2016) · Journal of Neurology · doi:10.1007/s00415-016-8362-2 · Cited by 13
Clinical trials in Alzheimer's disease
Delrieu, J., & Vellas, B. J. (2015) · Wiley eBooks · doi:10.1002/9781118323434.ch9 · Cited by 13
Volonté, C., Hu, G., Shaw, C. A., Claudio, V. J., dos Santos, J. A., Vaz, S. H., Sebastião, A. M., Balcar, V. J., Mozley, P. D., Verde, F., et al. (2026) · Exploration of Neuroprotective Therapy · doi:10.37349/ent.2026.1004136 · Cited by 12
van Etten, E. S., Mahinrad, S., Grill, J. D., Salloway, S., Atri, A., Cogswell, P. M., Benzinger, T. L. S., Iwatsubo, T., Iadecola, C., Lemere, C. A., et al. (2026) · Alzheimer s & Dementia · doi:10.1002/alz.71361 · Cited by 16
Self-citationApproaches for Increasing Cerebral Efflux of Amyloid-β in Experimental Systems
Loeffler, D. A. (2024) · Journal of Alzheimer s Disease · doi:10.3233/jad-240212 · Cited by 12
Sheikh‐Bahaei, N., Manavaki, R., Sajjadi, S. A., Priest, A. N., O'Brien, J. T., & Gillard, J. H. (2019) · Journal of Alzheimer s Disease · doi:10.3233/jad-180443 · Cited by 13
Yaari, R., Holdridge, K. C., Choi, J. S., Donohue, M., Kantarci, K., Jack, C. R., Zuk, S. M., Sims, J. R., Johnson, K. A., Aisen, P. S., et al. (2022) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2022.56 · Cited by 15
Self-citationAmyloid-Related Imaging Abnormalities in AβPP Duplication Carriers
Chamard-Witkowski, L., Wallon, D., Pijoff, A., Berger, É., Viennet, G., Hannequin, D., & Magnin, É. (2013) · Journal of Alzheimer s Disease · doi:10.3233/jad-130629 · Cited by 12
Toda, Y., Iwatsubo, T., NAKAMURA, Y., Matsuda, N., Miyata, M., Jin, M., Chen, T., Kuribayashi, K., Tian, Y., Hughes, R. A., et al. (2024) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2024.106 · Cited by 11
Yan, L., Zhang, L., Xu, Z., & Luo, Z. Y. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1559447 · Cited by 13
Lecanemab appropriate use recommendations for clinical practice in the UK
Mummery, C. J., Rasmussen, J., Blackburn, D. J., Coulthard, E. J., Davies, R., Dorsey, R., Fox, N. C., Hosseini, A. A., Ivenso, C., Jones, M. S., et al. (2025) · Journal of Neurology Neurosurgery & Psychiatry · doi:10.1136/jnnp-2025-336597 · Cited by 11
Self-citationGenetic architecture of neurodegenerative dementias
Clarimón, J., Moreno–Grau, S., Cervera‐Carles, L., Dols‐Icardo, O., Sánchez‐Juan, P., & Ruiz, A. (2020) · Neuropharmacology · doi:10.1016/j.neuropharm.2020.108014 · Cited by 11
Pizzini, F. B., Conti, E., Bianchetti, A., Splendiani, A., Fusco, D., Caranci, F., Bozzao, A., Landi, F., Gandolfo, N. G., Farina, L. M., et al. (2022) · La radiologia medica · doi:10.1007/s11547-022-01534-0 · Cited by 11
Lu, M., & Brashear, H. R. (2018) · Clinical Pharmacology in Drug Development · doi:10.1002/cpdd.584 · Cited by 11
Self-citationAPOE genotype and Alzheimer’s immunotherapy
Pankiewicz, J. E., & Sadowski, M. J. (2017) · Oncotarget · doi:10.18632/oncotarget.17990 · Cited by 11
Anti-amyloid treatments in Alzheimer’s disease: elegance, evidence and ethics
Daly, T. P., Olluri, A., & Kurkinen, M. T. (2024) · Advances in Clinical and Experimental Medicine · doi:10.17219/acem/198674 · Cited by 10
Cerebral Amyloid Angiopathy: Clinical Presentation, Sequelae and Neuroimaging Features—An Update
Weidauer, S., & Hattingen, E. (2025) · Biomedicines · doi:10.3390/biomedicines13030603 · Cited by 11
Takeuchi, L. E., Kalia, L. V., & Simmons, C. A. (2025) · Neurobiology of Disease · doi:10.1016/j.nbd.2025.106864 · Cited by 11
Kakeda, S., Miki, Y., Kudo, K., Mori, H., Tokumaru, A. M., Abe, O., Aoki, S., & Working Group for Brain MRI Guidelines for Anti-Aβ Antibody Treatment from The Japan Radiological Society, T. J. S. F. N. (2025) · Japanese Journal of Radiology · doi:10.1007/s11604-025-01773-x · Cited by 10
Alzheimer’s Disease Drug Development: A Research and Development Ecosystem
Cummings, J. L., Kinney, J. W., & Fillit, H. M. (2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759.002 · Cited by 10
Jian, J.-M., Fan, D., Tian, D., Cheng, Y., Sun, P., Tan, C., Zeng, G., He, C.-Y., Wang, Y., Zhu, J., et al. (2022) · Neuroscience Bulletin · doi:10.1007/s12264-022-00869-y · Cited by 11
Validation of 3‐ and 5‐point severity scales to assess ARIA‐E
Bracoud, L., Klein, G., Lyons, M., Scelsi, M. A., Wojtowicz, J., Bullain, S., Purcell, D. D., Fiebach, J. B., Barakos, J. A., & Suhy, J. (2023) · Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring · doi:10.1002/dad2.12503 · Cited by 10
Self-citationFloris, G., Stefano, F. D., Cherchi, M. V., Costa, G., Marrosu, F., & Marrosu, M. G. (2015) · Journal of Alzheimer s Disease · doi:10.3233/jad-150165 · Cited by 10
Neuroimaging Biomarkers in Alzheimer’s Disease
Khan, T. K. (2016) · Elsevier eBooks · doi:10.1016/b978-0-12-804832-0.00003-1 · Cited by 11
Immunotherapies Targeting α -Synuclein in Parkinson Disease
Jamal, F. (2020) · Federal Practitioner · doi:10.12788/fp.0026 · Cited by 10
Risacher, S. L. (2024) · CONTINUUM Lifelong Learning in Neurology · doi:10.1212/con.0000000000001509 · Cited by 11
Efficacy of antibody-based therapies to treat Alzheimer's disease: Just a matter of timing?
Cedernaes, J., Schiöth, H. B., & Benedict, C. (2014) · Experimental Gerontology · doi:10.1016/j.exger.2014.05.002 · Cited by 12
Wallin, A., Alladi, S., Black, S. E., Chen, C., Greenberg, S. M., Gustafson, D., Isaacs, J. D., Jokinen, H., Kalaria, R. N., Mok, V., et al. (2022) · Cerebral Circulation - Cognition and Behavior · doi:10.1016/j.cccb.2022.100044 · Cited by 10
Identifying Genetic Risk for Amyloid-Related Imaging Abnormalities
Hardy, J., & Schott, J. M. (2023) · Neurology · doi:10.1212/wnl.0000000000208096 · Cited by 11
Obrecht, M., Zurbruegg, S., Accart, N., Lambert, C., Doelemeyer, A., Ledermann, B., & Beckmann, N. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1177421 · Cited by 9
Geng, C., Tan, L., & Chen, C. (2024) · Brain Research · doi:10.1016/j.brainres.2024.148881 · Cited by 9
Leroi, I., Dolphin, H., Dinh, R., Foley, T., Kennelly, S., Kinchin, I., Ó’Caoimh, R., O’Dowd, S., O’Philbin, L., O’Reilly, S., et al. (2024) · BMC Health Services Research · doi:10.1186/s12913-024-11019-7 · Cited by 11
Gantenerumab for early Alzheimer’s disease: a systematic review and meta-analysis
de Almeida, A. M., Leite, M. G. H. S. J., Lopes, L. M., Lima, P. L. G., Barros, M. L. S., Pinheiro, S. L. R., Andrade, Í. B., Viana, P., Morbach, V., Marinheiro, G., et al. (2024) · Expert Review of Neurotherapeutics · doi:10.1080/14737175.2024.2367016 · Cited by 10
Ma, L., Wang, Y., Huynh, A. L. H., Amadoru, S., Wrigley, S., Yates, P. A., Masters, C. L., Goudey, B., Jin, L., & Pan, Y. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14602 · Cited by 9
Opportunities for Conformation-Selective Antibodies in Amyloid-Related Diseases
Westwood, M., & Lawson, A. D. G. (2015) · Antibodies · doi:10.3390/antib4030170 · Cited by 9
Aducanumab and disease modifying treatments for Alzheimer's disease
Thomas, E. S., Wasunna‐Smith, B., & Kuruvilla, T. (2021) · Progress in Neurology and Psychiatry · doi:10.1002/pnp.711 · Cited by 9
Alzheimer's Disease Drug Development
(2022) · Cambridge University Press eBooks · doi:10.1017/9781108975759 · Cited by 9
A Novel Small Molecule Modulator of Amyloid Pathology
Lovell, M. A., Lynn, B. C., Fister, S. X., Bradley‐Whitman, M. A., Murphy, M. P., Beckett, T. L., & Norris, C. M. (2016) · Journal of Alzheimer s Disease · doi:10.3233/jad-151160 · Cited by 9
Kelliny, S., Lam, H. Y., Parikh, A. R., Wang, Y., Bobrovskaya, L., Upton, R. N., & Zhou, X. (2020) · Current Drug Metabolism · doi:10.2174/1389200221666200502015203 · Cited by 9
Martens, R. M., Bechten, A., Ingala, S., van Schijndel, R. A., Machado, V. B., de Jong, M. C., Sánchez, E., Purcell, D. D., Arrighi, M., Brashear, R. H., et al. (2017) · European Radiology · doi:10.1007/s00330-017-5022-6 · Cited by 9
Rech, M. A., Carpenter, C. R., Aggarwal, N. T., & Hwang, U. (2025) · Annals of Emergency Medicine · doi:10.1016/j.annemergmed.2024.12.002 · Cited by 8
Diagnosis, pathomechanisms and therapy of cerebral amyloid angiopathy-related inflammation (CAA-ri)
Seifert, R. M., Klingebiel, R., & Schäbitz, W. (2025) · Neurological Research and Practice · doi:10.1186/s42466-025-00382-3 · Cited by 8
Frederiksen, K. S., Boada, M., Dubois, B., Engelborghs, S., Frisoni, G. B., Georges, J., Hort, J., Jönsson, L., Kramberger, M. G., Ousset, P., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01766-y · Cited by 9
Building a potent TREM2 agonistic, biparatopic, common light chain antibody
Almeida, A. R., Geddie, M. L., Bhate, A., Quan, C., Arndt, J. W., Jiao, Y., Santoro, J. C., Noiman, L., Vijayakumar, R., Sanchez-Salazar, J., et al. (2025) · mAbs · doi:10.1080/19420862.2025.2546554 · Cited by 8
Advances of therapeutic strategies for Alzheimer’s disease
Guo, X., Yue, R.-Z., Cui, Z., Wang, S., Jia, T., Li, W., Zhang, W., Shan, L., & Li, C. (2025) · Journal of Neurology · doi:10.1007/s00415-025-13456-8 · Cited by 9
Chu, C., Wang, Y., Ma, L., Mutimer, C. A., Ji, G., Shi, H., Yassi, N., Masters, C. L., Goudey, B., Jin, L., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.14583 · Cited by 8
Combination Drug Therapy for the Treatment of Alzheimer’s Disease
Alvarez, X. A., Linares, C., & Masliah, E. (2012) · European Neurological Review · doi:10.17925/enr.2012.07.02.92 · Cited by 9
Amyloid-β related angiitis presenting as eosinophilic meningitis: a case report
Tanner, J. A., Richie, M. B., Cadwell, C. R., Eliaz, A., Kim, S., Haq, Z., Rasool, N., Shah, M. P., & Guterman, E. L. (2022) · BMC Neurology · doi:10.1186/s12883-022-02638-w · Cited by 8
Wang, Y., Wang, M., Zeng, X., Liu, Y.-H., & Wang, Y. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220775 · Cited by 9
Should Canadian patients look forward to aducanumab for Alzheimer disease?
Watt, J. A., Marple, R., Hemmelgarn, B. R., & Straus, S. E. (2021) · Canadian Medical Association Journal · doi:10.1503/cmaj.211134 · Cited by 8
Brooks, D. J. (2020) · Seminars in Nuclear Medicine · doi:10.1053/j.semnuclmed.2020.12.001 · Cited by 8
Self-citationGrenon, M. B., Papavergi, M.-T., Bathini, P., Sadowski, M. J., & Lemere, C. A. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25115754 · Cited by 7
Sadruddin, Z., Harris, K., Bilsborough, E., Sciba, L., Vargas, A. F., Shyer, M. N., Hinojosa, M., Colby, J., Chung, K., Farrell, C. M., et al. (2025) · Geriatric Nursing · doi:10.1016/j.gerinurse.2025.05.010 · Cited by 7
Lohner, V., Badhwar, A., Detcheverry, F. E., García, C. L., Gellersen, H. M., Khodakarami, Z., Lattmann, R., Li, R., Low, A., Mazo, C., et al. (2025) · Alzheimer s Research & Therapy · doi:10.1186/s13195-025-01815-6 · Cited by 7
Saguer, I. L., & Oxtoby, N. P. (2024) · Brain Communications · doi:10.1093/braincomms/fcae438 · Cited by 7
Ge, W., Yan, Y., Hu, Y., Lin, S., & Mao, P. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877241307246 · Cited by 7
Yu, W., Zhang, R., Zhang, A., & Mei, Y. (2025) · International Journal of Molecular Sciences · doi:10.3390/ijms26031234 · Cited by 7
Zedde, M., Piazza, F., & Pascarella, R. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14051697 · Cited by 9
Caselli, R. J. (2012) · Alzheimer s Research & Therapy · doi:10.1186/alzrt123 · Cited by 7
Nakamura, T., Kawarabayashi, T., Ueda, T., Shimomura, S., Hoshino, M., Itoh, K., Ihara, K., Nakaji, S., Takatama, M., Ikeda, Y., et al. (2023) · Journal of Alzheimer s Disease · doi:10.3233/jad-220996 · Cited by 8
Taming Alzheimer's disease: New perspectives, newer horizons.
Sen, D., Majumder, A., Arora, V., Yadu, N., & Chakrabarti, R. (2017) · PubMed Central · Cited by 7
Les nouveaux traitements de la maladie d’Alzheimer
Delrieu, J., & Vellas, B. J. (2020) · Bulletin de l Académie Nationale de Médecine · doi:10.1016/j.banm.2020.01.018 · Cited by 11
Hainline, C., Rucker, J. C., Zagzag, D., Golfinos, J. G., Lui, Y. W., Liechty, B., Warren, F. A., Balcer, L. J., & Galetta, S. L. (2017) · Journal of Neuro-Ophthalmology · doi:10.1097/wno.0000000000000474 · Cited by 7
Altered Clearance and Amyloid-Related Imaging Abnormalities
Cogswell, P. M., Burkett, B. J., Johnson, D. R., & Pillai, J. J. (2025) · Neuroimaging Clinics of North America · doi:10.1016/j.nic.2024.12.002 · Cited by 6
Regional effects of gantenerumab on neuroimaging biomarkers in the DIAN‐TU‐001 trial
McCullough, A. A., Chen, C. D., Gordon, B. A., Joseph‐Mathurin, N., Jack, C. R., Koeppe, R., Hornbeck, R. C., Koudelis, D., McKay, N. S., Hobbs, D. A., et al. (2025) · Alzheimer s & Dementia · doi:10.1002/alz.70347 · Cited by 6
Self-citationMansfield, C. A., Bullok, K. E., Fuhs, J. V., Tockhorn‐Heidenreich, A., Andrews, J. S., DiBenedetti, D. B., Matthews, B. R., Darling, J. C., Sutphin, J., & Hauber, B. (2022) · Patient · doi:10.1007/s40271-022-00576-w · Cited by 6
Sakai, K., Noguchi‐Shinohara, M., Tanaka, H., Ikeda, T., Hamaguchi, T., Kakita, A., Yamada, M., & Ono, K. (2022) · Journal of Alzheimer s Disease · doi:10.3233/jad-220838 · Cited by 6
Genetic and degenerative disorders primarily causing dementia
Masdeu, J. C., & Pascual, B. (2016) · Handbook of clinical neurology · doi:10.1016/b978-0-444-53485-9.00026-x · Cited by 6
Targeting apolipoprotein E for treating Alzheimer’s disease
Bales, K. R., & Paul, S. M. (2019) · Neuroscience Letters · doi:10.1016/j.neulet.2019.134366 · Cited by 7
Ji, S.-L., Wang, W., Ma, S., Zhang, P., Xiang, Z., Liu, G., Wu, J., Wang, K., & Pan, J. (2025) · Talanta · doi:10.1016/j.talanta.2025.129169 · Cited by 5
Villarejo‐Galende, A., González‐Sánchez, M., Hilario, A., Velasco, S. L., Morenas‐Rodríguez, E., Muñoz-García, M. I., Ramos‐González, A., Pérez-Martínez, D. A., & Blanco-Palmero, V. A. (2025) · Journal of Alzheimer s Disease · doi:10.1177/13872877251404505 · Cited by 5
Bathini, P., Schilling, S., Rahfeld, J., Holtzman, D. M., Saido, T. C., & Lemere, C. A. (2026) · Molecular Neurodegeneration · doi:10.1186/s13024-026-00965-x · Cited by 6
Disease-specific adaptive immune biomarkers in Alzheimer's disease and related pathologies
Dorothée, G., Sarazin, M., & Aucouturier, P. (2013) · Revue Neurologique · doi:10.1016/j.neurol.2013.07.023 · Cited by 5
Neuroimaging of therapy-associated brain tissue abnormalities
Linn, J. (2014) · Current Opinion in Neurology · doi:10.1097/wco.0000000000000108 · Cited by 5
Sotoudeh, H., Alizadeh, M., Shahidi, R., Shobeiri, P., love, N., & Singhal, A. (2022) · Radiology Case Reports · doi:10.1016/j.radcr.2022.10.023 · Cited by 5
Novel immunological approaches for the treatment of Alzheimer's disease.
Sabharwal, P., & Wısnıewskı, T. (2014) · PubMed · doi:10.3969/j.issn.1672-6731.2014.03.001 · Cited by 5
Relapsing cerebral amyloid angiopathy-related inflammation: the wax and the wane
Salam, S., Anandarajah, M., Al–Bachari, S., Pal, P., Sussman, J., & Hamdalla, H. H. M. (2017) · Practical Neurology · doi:10.1136/practneurol-2017-001599 · Cited by 5
Five-year outcomes after IVIG for mild cognitive impairment due to alzheimer disease
Kile, S. J., Au, W. J., Parise, C. A., Rose, K., Donnel, T., Hankins, A. I., Au, Y., Chan, M., & Ghassemi, A. (2021) · BMC Neuroscience · doi:10.1186/s12868-021-00651-2 · Cited by 5
The Ups and Downs of Amyloid in Alzheimer's
Siemers, E., Aisen, P. S. S., & Carrillo, M. C. (2021) · The Journal of Prevention of Alzheimer s Disease · doi:10.14283/jpad.2021.54 · Cited by 5
Amyloid: Vascular and Parenchymal ☆
Weller, R. O., Carare, R.-O., & Boche, D. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.02590-6 · Cited by 5
Radiological Findings of Drug-Induced Neurotoxic Disorders
Godi, C., & Falini, A. (2019) · Springer eBooks · doi:10.1007/978-3-319-68536-6_67 · Cited by 5
Frisoni, G. B. (2012) · The Lancet Neurology · doi:10.1016/s1474-4422(12)70021-2 · Cited by 5
Zavarella, M., Cecchetti, G., Rugarli, G., Ghirelli, A., Bottale, I., Orlandi, F., Spinelli, E. G., Santangelo, R., Caso, F., Calloni, S. F., et al. (2025) · Journal of Neurology · doi:10.1007/s00415-025-12910-x · Cited by 4
Finn, Q., Pascual, B., Schulz, P. E., & Masdeu, J. C. (2025) · American Journal of Neuroradiology · doi:10.3174/ajnr.a9111 · Cited by 4
The potential of low-field MRI for global dementia care
Evans, T. E., Harper, J. R., Salehi, A., WEBB, A. G., Cole, J. H., Correa, A., Adams, H. H. H., Cash, D. M., & Jones, D. K. (2026) · Nature Reviews Neurology · doi:10.1038/s41582-026-01199-7 · Cited by 4
Welikovitch, L. A., Oakley, D. H., Bennett, R. E., Serrano‐Pozo, A., Zhu, H., Ruiz‐Uribe, N. E., Zwang, T. J., Chibnik, L. B., Gómez‐Isla, T., Frosch, M. P., et al. (2026) · Acta Neuropathologica · doi:10.1007/s00401-026-03037-y · Cited by 4
Self-citationWeidauer, S., Tafreshi, M., Förch, C., Hattingen, E., Arendt, C. T., & Friedauer, L. (2024) · European Journal of Neurology · doi:10.1111/ene.16425 · Cited by 4
Jeong, S. Y., Suh, C. H., Lim, J., Choi, Y., Kim, H. S., Kim, S. J., & Lee, J. (2025) · Journal of the Korean Society of Radiology · doi:10.3348/jksr.2024.0140 · Cited by 4
Metadata
- Authors
- Sperling, R., Salloway, S., Brooks, D. J., Tampieri, D., Barakos, J., Fox, N. C., Raskind, M., Sabbagh, M., Honig, L. S., Porsteinsson, A. P., Lieberburg, I., Arrighi, H. M., Morris, K. A., Lu, Y., Liu, E., Gregg, K. M., Brashear, H. R., Kinney, G. G., Black, R., & Grundman, M.
- Affiliations
- Brigham and Women's Hospital (US)
- Butler Hospital (US)
- Imperial College London (GB)
- McGill University (CA)
- California Pacific Medical Center (US)
- UCL Queen Square Institute of Neurology (GB)
- Columbia University (US)
- University of Rochester Medicine (US)
- University of California, San Francisco (US)
- Janssen Alzheimer Immunotherapy Research & Development (United States) (US)
- Corresponding author
- Sperling, Reisa
- ORCID
- Venue
- The Lancet Neurology
- Publisher
- Elsevier BV
- Published
- 2012-03
- Volume
- 11
- Issue
- 3
- Pages
- 241-249
- ISSN
- 1474-4422 (ISSN-L)
- PMC
- PMC4063417
- OpenAlex
- W2122843800
- Cited by
- 512
- References
- 27
- Citations by year
- 2026: 25 · 2025: 41 · 2024: 51 · 2023: 35 · 2022: 47 · 2021: 32 · 2020: 31 · 2019: 25 · 2018: 22 · 2017: 34 · 2016: 29 · 2015: 47 · 2014: 36 · 2013: 39 · 2012: 17
- FWCI
- 29.81
- Type
- journal article
- Language
- en
- Open access
- green
- www.ncbi.nlm.nih.gov
- Locations
- The Lancet Neurology (publishedVersion)
- PubMed (publishedVersion)
- Amsterdam UMC (VU Amsterdam) - Institutional Repository (publishedVersion)
- Europe PMC (PubMed Central) (acceptedVersion)
- PubMed Central (acceptedVersion)
- Digital Academic REpository of VU University Amsterdam (Vrije Universiteit Amsterdam) (submittedVersion)
- UCL Discovery (University College London) (submittedVersion)
- Pure Amsterdam UMC (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion)
- Funders
- National Institute for Health and Care Research (NF-SI-0508-10123)
- Elan
- National Institute on Aging (K24AG035007, P50AG005134, P30AG062421)
- Topics
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Alzheimer's disease research and treatments
- Health Sciences › Medicine › Psychiatry and Mental health › Dementia and Cognitive Impairment Research
- Health Sciences › Medicine › Clinical Neurology › Intracerebral and Subarachnoid Hemorrhage Research
- Keywords
- amyloid-related imaging abnormalities, bapineuzumab, Alzheimer's disease, amyloid-beta, ARIA-E, ARIA-H, vasogenic edema, microhemorrhages, APOE ε4, dose-dependent risk, risk factors, FLAIR MRI, adverse events
- MeSH terms
- Aged, Aged, 80 and over, Alzheimer Disease, Brain, Female, Humans, Magnetic Resonance Imaging, Male, Middle Aged, Retrospective Studies, Risk Factors, Amyloid beta-Peptides, Neuroimaging, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
